	US 11,752,193 B2
	Administering methylation-controlled J protein (MCJ) SIRNA to a kidney cell
Mercedes Rincon, Aurora, CO (US); and Ketki M. Hatle, Jamaica Plain, MA (US)
Assigned to University of Vermont and State Agricultural College, Burlington, VT (US)
Filed by University of Vermont and State Agricultural College, Burlington, VT (US)
Filed on Oct. 2, 2020, as Appl. No. 17/61,912.
Application 17/061,912 is a continuation of application No. 15/805,534, filed on Nov. 7, 2017, granted, now 10,792,330.
Application 15/805,534 is a continuation of application No. 14/413,927, granted, now 10,583,169, issued on Mar. 10, 2020, previously published as PCT/US2013/049885, filed on Jul. 10, 2013.
Claims priority of provisional application 61/670,345, filed on Jul. 11, 2012.
Prior Publication US 2021/0023172 A1, Jan. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 48/00 (2006.01); A61K 45/06 (2006.01); G01N 33/68 (2006.01)

CPC A61K 38/1709 (2013.01) [A61K 38/17 (2013.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); G01N 33/68 (2013.01)]

5 Claims

1. A method of increasing mitochondrial metabolism in a kidney cell, the method comprising contacting the kidney cell with an MCJ-modulating compound comprising an MCJ siRNA that decreases MCJ polypeptide activity in the kidney cell, in an amount effective to increase mitochondrial metabolism in the kidney cell.